The development of immune-checkpoint inhibitors (ICIs) has heralded a new era in cancer
treatment, enabling the possibility of long-term survival in patients with metastatic disease …

Melanoma, a skin cancer that develops from pigment cells, has been studied intensively,
particularly in terms of the immune response to tumours, and has been used as a model for …

Immune-related adverse events, particularly severe toxicities such as myocarditis, are major
challenges to the utility of immune checkpoint inhibitors (ICIs) in anticancer therapy. The …

Cancer immunotherapy has revolutionised cancer treatment, with immune checkpoint
blockade (ICB) therapy and adoptive cell therapy (ACT) increasingly becoming standard of …

Abstract 'Immune checkpoint blockade'for cancer describes the use of therapeutic antibodies
that disrupt negative immune regulatory checkpoints and unleash pre-existing antitumour …

In cancer-immunity cycle, the immune checkpoint PD1 and its ligand PDL1 act as
accomplices to help tumors resist to immunity-induced apoptosis and promote tumor …

The success of targeted therapies and immunotherapies has created optimism that cancers
may be curable. However, not all patients respond, drug resistance is common and many …

To dissect therapeutic mechanisms of transplanted stem cells and develop exosome-based
nanotherapeutics in treating autoimmune and neurodegenerative diseases, we assessed …

Immune checkpoint blockade targeting PD-1/PD-L1 has promising therapeutic efficacy in a
variety of tumors, but resistance during treatment is a major issue. In this review, we describe …

Identifying the mechanisms underlying the regulation of immune checkpoint molecules and
the therapeutic impact of targeting them in cancer is critical. Here we show that high …